Holmes Biopharma, Inc.
PINK SHEETS : HLMB

Holmes Biopharma, Inc.

September 27, 2007 03:00 ET

Holmes Biopharma: Strong Sales Growth Continues

SCOTTSDALE, ARIZONA--(Marketwire - Sept. 27, 2007) - Holmes Biopharma, Inc. (PINK SHEETS:HLMB) announces that 2007 revenue from its clinical research operations now exceeds $5 million. In addition, the company has more than $5 million in awarded contracts to be completed in the coming months.

The Company is currently expanding its facilities in Omaha, Nebraska and has added a clinic in Kiev, Ukraine. With the addition of these operations, management expects sales to grow by 100% in 2008.

About Holmes:

Holmes Biopharma, Inc. is a contract research organization focused on providing integrated and cost effective clinical development services that help the pharmaceutical industry introduce new drug products. Holmes is also actively involved in developing new drugs and drug delivery systems. Currently, clinics operate in Omaha, Nebraska; Kiev, Ukraine and Toronto, Canada. For more information about the company please visit our website at www.holmesbiopharma.com.

On behalf of the Board of Directors

John F. Metcalfe, President

Certain statements in this press release constitute "forward looking statements" within the meaning of the United States Securities Legislation. The Company's actual results could differ from those in the forward-looking statements. Do not construe this information as investment advice. This is not a solicitation to buy or sell securities. This does not purport to be a complete analysis of the Company. Investing in securities is speculative and carries a high degree of risk. Past performance does not guarantee future results. Readers should consult their own independent advisers with any investment, including any contemplated investment. All information contained in this press release should be independently investigated. This press release contains forward-looking statements. These remarks involve risks and uncertainties. Risks are not limited to quarterly fluctuations in results or the companies' management of growth and competition. Other risks are detailed in the Company's SEC filings. Actual results may differ materially from such information set forth herein.

Contact Information